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INTRODUCTION
The insulin receptor substrate (IRS)
proteins are key molecules in the signal-
ing pathways induced by insulin and in-
sulinlike growth factor 1 (IGF-1) and me-
diate their pleiotropic effects, including
cell growth, survival, development and
glucose metabolism (1).
Among the six known IRS proteins,
IRS1 and IRS2 serve as adaptor proteins
to both the insulin receptor (IR) and the
IGF-1 receptor (IGF1R), activating the
phosphatidylinositol 3-kinase and mito-
gen-activated protein kinase (MAPK)
pathways (2). Although IRS1 and IRS2
share similar expression patterns in most
tissues, several lines of evidence suggest
that IRS-mediated signaling in growth
and metabolism is tissue specific (3,4).
Mutations in IR and IGF1R lead to severe
defects in development and premature
death in mice and humans (5,6). How-
ever, deletion of mouse IRS proteins 1
and 2 produces growth retardation and
type 2 diabetes in mice, respectively (7,8).
IRS2 integrates the effects of insulin in
peripheral target tissues, mainly the liver,
with those of IGF-1 in pancreatic β cells
to maintain glucose homeostasis. Mice
lacking IRS2 exhibit impaired suppres-
sion of hepatic glucose production (8–10)
and β-cell failure (11), developing fasting
hyperglycemia at 6–8 wks of age and se-
vere type 2 diabetes at 10–12 wks of age
(8). IRS2 also coordinates IGF-1/ IGF1R
signaling in the central nervous system,
where this factor is essential for the regu-
lation of cell proliferation, growth, differ-
entiation and metabolic demands during
fetal and postnatal development (12).
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Human IGF1 mutations cause severe neu-
ral defects including microcephaly, men-
tal retardation and profound deafness
(13–16). Similarly, Igf1–/– mice exhibit de-
layed myelination (17,18), severe sen-
sorineural deafness (19,20) and progres-
sive blindness (21). The cochlea of
IGF-1–deficient mice presents an abnor-
mal tectorial membrane, increased neu-
ronal apoptosis, poor myelination of
nerve fibers (22,23) and impaired activa-
tion of protein kinase B (PKB; AKT) and
rapid accelerated fibrosarcoma (RAF) ki-
nases (24).
Irs2–/– mice also show impaired brain
growth (25), defects in myelination (26)
and increased apoptosis in the retina
(27). Therefore, there is a close relation-
ship between insulin and IGF-1 functions
and signaling pathways in the central
nervous system, reflected in the similar
neural phenotypes of both Irs2–/– and
Igf1–/– mice. However, the specific role of
IRS2 in the inner ear of the IRS2-deficient
mice remains unstudied.
Recently, it has been shown that the di-
abetic phenotype in IRS2-deficient mice
can be reverted by the inhibition of the
protein tyrosine phosphatase (PTP)-1B
(28,29). PTP1B directly interacts with
both IR and IGF1R and catalyzes the de-
phosphorylation of both tyrosine kinase
receptors (30,31). The importance of
PTP1B as a modulator of insulin action
has been shown both in vivo in liver and
muscle (32–34), as well as in cellular
models. Mice lacking the Ptpn1 gene ex-
hibit increased insulin sensitivity, resist-
ance to weight gain on a high-fat diet
and increased basal metabolic rate (35,36).
The role of PTP1B in IGF-1–mediated
signaling in nervous and sensorial sys-
tems remains less studied. Accordingly,
we have analyzed the hearing function
and cochlear morphology of Irs2–/– mice
and the impact of PTP1B deficiency.
MATERIALS AND METHODS
Mouse Housing and Handling
Three genetically modified mouse
strains (Irs2–/–Ptpn1+/+, Irs2+/+Ptpn1–/– and
Irs2–/–Ptpn1–/–) maintained in a mixed
C57BL/6 × 129/Sv genetic background
(28) were used in the study. Because the
impact of the Irs2 gene mutation on the
metabolic phenotype is variable (8,37),
the detailed study of hearing was carried
out only in male mice that developed
type 2–like diabetes, defined as glycemia
>300 mg/dL. Glucose concentration was
measured in tail-vein blood samples
using a blood glucose meter (Accu-
Check Aviva; Roche Diagnostics, Sant
Cugat del Vallés, Spain). Type 2–like dia-
betes in IRS2-deficient mice normally
starts at ~8 wks, with a high mortality
rate at ~16 wks of age as a result of dia-
betic complications (37). Considering this
time course, functional and morphologi-
cal assessment was performed in predia-
betic (young 3–5 wks old) and diabetic
(adult 8–16 wks old) mice. Fed glucose
levels were 123.8 ± 2.6, 198 ± 15.7, 118.6 ±
3.19 and 127.6 ± 3.5 mg per 100 mL in
Irs2+/+Ptpn1+/+, Irs2–/–Ptpn1+/+,
Irs2+/+Ptpn1–/– and Irs2–/–Ptpn1–/– 5-wk-
old mice, respectively. Fed glucose levels
were maintained in the normal range in
12-wk-old mice of the Irs2+/+Ptpn1+/+
(138.8 ± 2.6), Irs2+/+Ptpn1–/– (132.7 ± 3)
and Irs2–/–Ptpn1–/– (129.6 ± 3.5) geno-
types, but were dramatically increased to
426.8 ± 35.7 mg/100 mL in the
Irs2–/–Ptpn1+/+ mice.
Mice were fed ad libitum with a stan-
dard diet and drinking water and con-
trolled following Federation of European
Laboratory Animal Science Associations
(FELASA) recommendations. All animal
experimentation was conducted in ac-
cord with Spanish and European legisla-
tion and approved by the Spanish Na-
tional Research Council (CSIC) Animal
Care and Use Committee. 
Hearing Evaluation
Hearing was evaluated by studying
the auditory brainstem response (ABR)
following standard methods (19,20).
Click and 8- to 40-kHz tone burst stimuli
were generated with SigGenRP™ soft-
ware (Tucker-Davis Technologies,
Alachua, FL, USA) and presented from
90 to 20 decibel sound pressure level (dB
SPL) in 5–10 dB SPL steps. The electrical
response was amplified, recorded and
averaged, and hearing thresholds were
determined for each stimulus as de-
scribed (19). Peak and interpeak latencies
were analyzed at 90 dB SPL after click
stimulation. Irs2+/+Ptpn1+/+ mice of
matched ages were used as controls.
ABR data were analyzed using SPSS
v19.0 software. For each age group, ABR
parameters were compared among geno-
types with analysis of variance and Bon-
ferroni and Tamhane post hoc multiple
comparisons. The results were consid-
ered significant at P ≤ 0.05. Data in the
text are expressed as mean ± standard
deviation (SD).
Cochlear Morphology and Stereology
Mouse cochleae were processed as re-
ported (20,22). Cochleae were embed-
ded in paraffin wax (Panreac Quimica,
Castellar del Valles, Spain) or methacry-
late (Technovit 7100; Heraeus-Kulzer,
Wehrheim, Germany). Sections of 5 or
40 μm thickness were stained with
hematoxylin-eosin or 0.1% cresyl violet
(Fluka; Sigma-Aldrich Quimica, Tres
Cantos, Spain), respectively. Cochlear
morphology was studied with an Axio-
phot Zeiss microscope plus Olympus
DP70 digital camera. Immunohistochem-
ical studies were performed on paraffin
sections to detect myelin P0 (Neuromics;
1:100), neurofilament 200 kDa (Diagnos-
tic; 1:100), potassium channel Kir4.1
(Chemicon; 1:400) and myosin VIIa
(Proteus Biosciences; 1:100), combined
with the appropriate biotin- conjugated
secondary antibody solution (Chemicon;
dilution 1:200). A tertiary antibody solu-
tion (ExtrAvidin® peroxidase, combined
with 3,3-diaminobenzidine tetrahy-
drochloride [DAB] or Texas Red® Strep-
tavidin; Vector Laboratories; 1:200) was
used to detect biotin. Sections were
mounted in Entellan® (Merck Chemi-
cals, Mollet del Vallés, Spain) for light
microscopy or in Vectashield® (Vector
Laboratories) for confocal microscopy
analysis (Leica TCS SP2). Quantification
of myelin P0 immunoreactivity was per-
formed on photomicrographs taken
with 24 bits of red-green-blue (RGB)
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color depth using a 12-bit DP70 digital
camera in an Olympus BX51 micro-
scope. All pictures were taken with a
20× UPlanSApo Olympus objective,
using the same settings. Densitometry
of the immunoreactivity was performed
with National Institutes of Health (NIH)
Image J software. Optical density mea-
sures were obtained on  freehand-
delineated profiles covering all the cell
bodies present in four to five im-
munoreacted sections per case. Four
cases per group were studied.
The method of Cavalieri (38,39) was
used to estimate the total volume of
main cochlear structures, by point count-
ing on target regions identified in sys-
tematically sampled sections throughout
the cochlea. The interactive test grids and
control of the motorized stage were pro-
vided by the CAST stereological software
package (v.2,3,2,0; Visiopharm). Live im-
ages were captured with an Olympus
DP70 solid-state video camera and pro-
jected on a high-resolution video monitor
at a magnification of 300×. Every third
section of the cochlea was studied, which
enabled 5–11 sections of each target
structure to be sampled and measured.
The precision of the estimates was deter-
mined by the coefficient of error (CE) as
described for systematic random samples
(37). The different average CEs obtained
with this sampling scheme ranged be-
tween 3% and 7%. Volume estimates
were not corrected for shrinkage.
Cochlear Protein Extraction and
Western Blot Analysis
Frozen cochleae from 5-wk-old mice
were pooled (three mice per genotype)
and lysed in 200 μL ice-cold radioim-
munoprecipitation assay buffer contain-
ing 0.01% of protease and phosphatase
inhibitor cocktails (P8340, P5726; Sigma
Aldrich) and cochlear extracts prepared
as reported (24). Protein concentration
was determined by Micro BCA Protein
Assay Kit (PIERCE Biotechnology-
Thermo Fisher Scientific) using bovine
serum albumin (BSA) as the standard.
Analysis of protein expression was per-
formed by Western blotting. Cochlear
proteins were subjected to sodium
 dodecyl sulfate–polyacrylamide gel
electrophoresis and transferred to
polyvinylidene fluoride membranes in a
Bio-Rad Trans Blot apparatus. After in-
cubation with a blocking solution, the
membranes were probed overnight at
4°C with primary antibodies for
 phospho-p38 MAPK (Cell Signaling
Technologies; 1:1,000), phospho-p44/42
MAPK (Cell Signaling Technologies;
1:5,000), PTP-1B (Millipore; 1:5,000), 
p-Akt1/2/3 (Ser 473)-R (Santa Cruz
Biotechnology; 1:1,000) and p38α (Santa
Cruz Biotechnology; 1:5,000) as a load-
ing control. Antibodies were diluted in
Tris-buffered saline with Tween contain-
ing 5% BSA for phosphorylation- specific
 antibodies or nonfat dried milk for oth-
ers. The membranes were washed and
incubated with the corresponding
 peroxidase-conjugated secondary anti-
bodies for 1 h at room temperature. Im-
munoreactive bands were visualized by
enhanced chemiluminescence (GE
Healthcare) using X-ray films (Agfa),
and the bands were quantified by den-
sitometry with NIH Image J software.
Different exposure times were used to
ensure that bands were not saturated.
Statistical significance was estimated by
Student t test. P values of <0.05 were
considered significant.
RESULTS
IRS2 Deficiency Results in Congenital
Sensorineural Deafness in Mice
Irs2+/+Ptpn1+/+ (hereafter referred as
wild-type) mice analyzed at 3–5 wks of
age showed normal hearing thresholds
and ABR wave patterns, whereas
Irs2–/–Ptpn1+/+ mice presented a profound
sensorineural deafness with no ABR re-
sponse to stimuli below 70 dB SPL.
These differences in hearing phenotype
were maintained in the adult 8- to 16-
wk-old mice group (Figure 1A).
Irs2–/–Ptpn1+/+ mice showed significantly
(P ≤ 0.001) elevated hearing thresholds in
response to click stimulus at both 3–5 wks
(80 ± 10 dB SPL, n = 7) and 8–16 wks 
(79 ± 8, n = 18), compared with wild-type
mice of matched ages (39 ± 3 dB SPL, n =
9, and 36 ± 4, n = 8, respectively) (Figure
1B and Table 1). Accordingly, both 3- to
5-wk-old and 8- to 16-wk-old deaf
Irs2–/–Ptpn1+/+ mice presented a signifi-
cant (P ≤ 0.001) hearing loss at all fre-
quencies studied, but with high frequen-
cies (28 and 40 kHz) being most affected,
whereas control wild-type mice pre-
sented normal hearing thresholds at all
frequencies studied (Figure 1C). Differ-
ences in ABR thresholds for pure tones
between Irs2–/–Ptpn1+/+ mice and wild-
type counterparts were of 30–40 dB SPL
(Table 1).
Peak latencies of Irs2–/–Ptpn1+/+ mice
were significantly increased, thus sug-
gesting a delay in the transmission of the
stimulus from the cochlea to the inferior
colliculus in the brainstem. Concretely,
peak I latency in Irs2–/–Ptpn1+/+ mice was
significantly greater (P ≤ 0.001, n = 6)
than in wild-type mice. In addition, sta-
tistically significant differences were
found in interpeak latencies II–IV and
I–IV. Therefore, the delay in transmission
originates in the cochlea and is main-
tained along the auditory pathway
(Table 1 and Figure 1D). The increase in
ABR thresholds and peak I latency ob-
served in the young Irs2–/–Ptpn1+/+ mice
and sustained through time suggest that
the deficiency of IRS2 is associated with
congenital neurosensorial deafness that
could not be compensated during
cochlear postnatal maturation.
The amplitude/intensity and
latency/intensity curves for peak I in
both young and adult Irs2–/–Ptpn1+/+
mice were also altered. Peak I ampli-
tudes were lower than those from wild-
type mice, whereas the curve for peak I
latency was situated above that of wild-
type mice (data not shown).
PTP1B Deficiency Does Not Affect
Hearing and Improves Hearing
Function in IRS2-Deficient Mice
To study the effect of the absence of
PTP1B in the hearing function of IRS2-
deficient mice, Irs2+/+Ptpn1–/– and
Irs2–/–Ptpn1–/– mice were studied.
Irs2+/+Ptpn1–/– mice did not exhibit any
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obvious alteration in the ABR parameters
and presented mean click threshold val-
ues similar to, and frequently even better
than those of wild-type mice (3- to 5-wk-
old mice, 36 ± 4 dB SPL, n = 10; 8- to 16-
wk-old mice: 38 ± 4, n =9; Figures 1A, B;
Table 1). In addition, the audiogram of
both young and adult Irs2+/+Ptpn1–/–
mice was similar to that of wild-type
mice, with ABR thresholds in response to
tone bursts ~40 dB SPL for all the fre-
quencies analyzed (Figure 1C; Table 1).
No significant differences were found in
peak I latency compared with wild-type
mice (Table 1). Both amplitude-intensity
and latency-intensity curves in
Irs2+/+Ptpn1–/– mice were similar to those
of wild-type mice at the two ages ana-
lyzed (not shown).
Interestingly, whereas young
Irs2–/–Ptpn1–/– mice did not show hearing
loss, the adult population presented
signs of deafness. Accordingly,
Irs2–/–Ptpn1–/– mice at 8–16 wks of age
displayed moderate deafness with ABR
click thresholds of 69 ± 10 dB SPL (n = 8),
which showed significant differences
when compared with wild-type mice 
(P ≤ 0.001, n = 8) and Irs2+/+Ptpn1–/– mice
(P ≤ 0.001, n = 9), and even when com-
pared with severely deaf Irs2–/–Ptpn1+/+
mice (P < 0.05, n = 18) (Figure 1B, Table 1).
Adult Irs2–/–Ptpn1–/– mice also showed an
impaired response to pure tone bursts,
especially at high frequencies (Figure 1C,
Table 1) and elevated interpeak latencies
(Table 1) associated with aging. In addi-
tion, amplitude-intensity and latency-
 intensity curves in adult Irs2–/–Ptpn1–/–
mice were close to those of Irs2–/–Ptpn1+/+
mice (not shown). Therefore, the con-
comitant absence of PTP1B delayed the
onset of the deafness.
IRS2-Deficient Mice Present
Alterations in the Stria Vascularis and
Cochlear Ganglion
General cochlear morphology of wild-
type, Irs2–/–Ptpn1+/+ and Irs2–/–Ptpn1–/–
mice were similar at both ages, and the
main cochlear structures in the scala
media showed an apparent normal cy-
toarchitecture (Figures 2A–I). Accordingly,
Figure 1. Hearing function. (A) Representative ABR recordings in response to click stim-
uli of wild-type, Irs2–/–Ptpn1+/+ and Irs2–/–Ptpn1–/– mice at 5 (upper row) and 11 (bottom
row) wks of age. IRS2-deficient mice showed profound deafness compared with the
normal ABR pattern of the wild-type mice, at both ages studied. Double-null mice 
developed severe hearing loss during the time window studied. (B) ABR thresholds
(mean ± standard error of the mean [SEM]) in response to click stimuli in wild-type ( ),
Irs2–/–Ptpn1+/+ ( ), Irs2+/+Ptpn1–/– ( ) and Irs2–/–Ptpn1–/– ( ) mice, at both ages studied.
Wild-type and Irs2+/+Ptpn1–/– mice maintained normal hearing thresholds during the
study. Statistically significant differences were found between IRS2-deficient mice and
normal hearing genotypes at both ages (***P < 0.001), whereas double-null mice pre-
sented significantly raised thresholds only in adulthood (###P < 0.001). (C) ABR thresholds
in response to tone burst stimuli (8–40 kHz) in wild-type (), Irs2–/–Ptpn1+/+ (),
Irs2+/+Ptpn1–/– () and Irs2–/–Ptpn1–/– () at both ages studied. Irs2-null mice showed an
all- frequency involved hearing loss, with statistically significant differences compared
with wild-type (***P < 0.001) and Irs2+/+Ptpn1–/– mice, which maintained normal thresh-
olds throughout the study. The lack of PTP1B in Irs2–/–Ptpn1–/– mice delayed and tem-
pered the increase of the audiogram with statistically significant differences, with con-
trol mice appearing only in the adult age (###P < 0.001). Thresholds for 4 and 40 kHz
were significantly lower in double-null mice compared with Irs2–/–Ptpn1+/+ mice (†P <
0.05). (D) Scheme of the auditory pathway, indicating the main structures and the cor-
respondence with ABR peaks. Cochlear ganglion neurons connect with the cochlear
nuclei, which project into the lateral lemniscus via acoustic striae and afterwards in the
nucleus of the inferior colliculus. Neurons in the inferior colliculus project to the medial
geniculate body of the thalamus that sends tonotopical projections to the primary au-
ditory cortex. Several accessory auditory brain stem nuclei send both crossed and un-
crossed projections through the lateral lemniscus.
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the sensory hair cells in the organ of Corti
appeared normal (Figures 2J, L, N), and
the pattern of expression of myosin VIIa,
a specific marker for the inner and outer
hair cells, was similar in the mutant and
wild-type mice (Figures 2K, M, O).
The stria vascularis is a three-layer
structure, formed by marginal, interme-
diate and basal cells and highly vascular-
ized by intraepithelial capillaries, which
produces the endolymph and maintains
the endocochlear potential (Figure 2C).
In wild-type mice, the stria vascularis
showed a normal histological organization
and capillary network (Figures 3A, C),
with the marginal cells displaying exten-
sive folds surrounding the endostrial
capillaries (Figures 3B, D), as well as a
normal pattern of expression of the potas-
sium channel Kir4.1 (40) (Figures 3E, F).
In contrast, the Irs2–/–Ptpn1+/+ mice
showed traits of strial atrophy at both
ages (Figure 3G–J, brackets), including
marginal cell degeneration (Figures 3G–J,
arrows), dilatation or merging of the
capillaries (Figures 3G, H; dashed ar-
rows) and altered Kir4.1 expression (Fig-
ures 3K, L). Accordingly, stereological
evaluation of strial volume showed a sig-
nificant decrease in Irs2–/–Ptpn1+/+ mice
when compared with wild-type mice
(Figure 4, stria vascularis [StV]). In the
Irs2–/–Ptpn1–/– mice, the stria vascularis
did not show gross volume changes, al-
though signs of degeneration were evi-
dent (Figures 3M–P), showing a large
number of merged capillaries, specially
at 11 wks of age (Figures 3O, P; dashed
arrows) and altered Kir4.1 expression
(Figures 3Q, R).
Histological analysis of the cochlear
ganglia showed a similar cellular organi-
zation among genotypes (Figures 5A–C).
However, since alterations in the myelina-
tion of IRS2-deficient mice have been re-
ported (26), myelin P0 was used to detect
possible defects in this process. Indeed, 11-
wk-old Irs2–/–Ptpn1+/+ and Irs2–/–Ptpn1–/–
mice showed alterations in the myelin P0
expression pattern compared with wild-
type mice (Figures 5D–F). Quantification
of myelin P0 immunoreactivity in the
cochlear ganglion indicated a statistically
significant reduction in Irs2–/–Ptpn1+/+
(43.9%, P < 0.05) and Irs2–/–Ptpn1–/–
(33.8%, P < 0.05) mice regarding wild-type
mice values. Accordingly, both myelin P0
and neurofilament 200-kDa immunostain-
ing of fibers projecting from the cochlear
ganglion to the sensory cells were also al-
tered in IRS2-deficient mice (Figures 5H, I,
K, L; arrows) compared with wild-type
mice (Figures 5G, J), thus suggesting
deficits in the density of innervation of the
hair cells, in concordance with the reduc-
tion in the cochlear ganglion volume (Fig-
ure 4; SG).
In contrast to IRS2-deficient mice and
accordingly with the functional data,
Table 1. ABR thresholds and latencies.
Genotype
Age 3–5 wks Age 8–16 wks
Irs2+/+Ptpn1+/+ Irs2–/–Ptpn1+/+ Ptpn1–/–Irs2+/+ Irs2–/–Ptpn1–/– Irs2+/+Ptpn1+/+ Irs2–/–Ptpn1+/+ Ptpn1–/–Irs2+/+ Irs2–/– Ptpn1–/–
n 9 7 10 6 8 18 9 8
ABR threshold (dB SPL)
Click 39 ± 3 80 ± 10a 36 ± 4 38 ± 3 36 ± 4 79 ± 8a 38 ± 4 69 ± 10a
8 kHz 39 ± 5 73 ± 6a 42 ± 4 42 ± 4 39 ± 6 81 ± 8a 43 ± 5 69 ± 17a
16 kHz 37 ± 7 67 ± 6a 35 ± 12 35 ± 3 35 ± 5 72 ± 10a 37 ± 5 67 ± 12a
20 kHz 39 ± 7 80 ± 10a 41 ± 8 40 ± 8 39 ± 7 82 ± 11a 40 ± 6 71 ± 15a
40 kHz 49 ± 4 90 ± 10a 48 ± 6 50 ± 7 43 ± 5 90 ± 7a 47 ± 8 77 ± 16a
n 9 6 9 6 8 18 9 8
Peak latency (ms)
I 1.28 ± 0.08 1.39 ± 0.14a 1.35 ± 0.0 1.32 ± 0.06 1.28 ± 0.09 1.32 ± 0.08c 1.30 ± 0.10 1.26 ± 0.09
II 2.16 ± 0.09 2.30 ± 0.13b 2.36 ± 0.07c 2.28 ± 0.05 2.20 ± 0.12 2.17 ± 0.12 2.12 ± 0.10c 2.16 ± 0.04
IV 3.88 ± 0.12 4.14 ± 0.90a 4.48 ± 0.20 4.22 ± 0.09a 3.85 ± 0.15 3.93 ± 0.14 3.83 ± 0.14 3.96 ± 0.15
Interpeak latency (ms)
I–II 0.87 ± 0.10 0.90 ± 0.05 1.01 ± 0.07c 0.95 ± 0.04b 0.92 ± 0.10 0.84 ± 0.09c 0.82 ± 0.11c 0.90 ± 0.08
II–IV 1.72 ± 0.13 1.84 ± 0.09c 2.12 ± 0.16 1.94 ± 0.06a 1.65 ± 0.14 1.76 ± 0.09c 1.71 ± 0.08 1.79 ± 0.11c
I–IV 2.59 ± 0.09 2.75 ± 0.12c 3.13 ± 0.21 2.89 ± 0.06a 2.57 ± 0.10 2.60 ± 0.13 2.53 ± 0.15 2.69 ± 0.15
ABR thresholds (mean ± SD in dB SPL) in response to click and tone burst (4–40 kHz) stimuli were determined in young (3- to 5-wk-old) and
adult (8- to 16-wk-old) mice from the four genotypes analyzed. Click ABR peak and interpeak latencies (mean ± SD, in ms) are shown in
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general cochlear morphology in
Irs2+/+Ptpn1–/– mice was similar to that of
control mice (Figures 6A, B), and the
main cochlear structures, including
cochlear ganglion and stria vascularis
presented normal features (Figures 6C–H),
with the later showing a normal pattern
of expression of the potassium channel
Kir4.1 compared with control mice (Fig-
ures 6I, J).
Analysis of the IGF-1 Signaling
Pathways in IRS2-Deficient Mice
The levels of PTP1B, p-AKT, p-p38 and
p-p44/42 MAPKs were measured by
Western blotting in 5-wk-old mice
cochleae. MAPKs play an important role
in inner ear development. Alterations in
the phosphorylation levels of MAPKs
and AKT in the deaf Igf1-null mouse
have been described (24,41). PTP1B pro-
tein was expressed in the cochlea of the
wild-type and Irs2–/–Ptpn1+/+ mice.
PTP1B was slightly increased in IRS2-
 deficient mice (Figure 7) as reported pre-
viously (28). As expected, PTP1B expres-
sion was totally lost in the Irs2+/+Ptpn1–/–
(Figure 7) and Irs2–/–Ptpn1–/– mice (not
shown). IGF-1 signaling pathways were
studied, and a statistically significant re-
duction in the levels of p-MAPK was ob-
served in the 5-wk-old double mutant
mice, as reported for the Igf1–/– mouse
(24). In contrast, the phosphorylation
 levels of AKT and p38α did not show
differences.
DISCUSSION
IRS2 coordinates IGF-1/IGF1R signal-
ing in the nervous system, and accord-
ingly, its deletion in mice leads to re-
duced neural proliferation during
development (25), defects in appropriate
timing of myelination (26) and loss of
retinal photoreceptors by increased apo-
ptosis (27). Given the similar neural
phenotype of both Igf1- and Irs2-null
mice, we hypothesized that lack of IRS2
could also lead to hearing impairment
in the same way as it happens in Igf1–/–
mice (14,19). Here we have investigated
for the first time the hearing function
and cochlear morphology of
Irs2–/–Ptpn1+/+ mice and the effects of ge-
netic ablation of PTP1B.
The hearing phenotype in Irs2–/–Ptpn1+/+
mice included increased ABR thresholds,
particularly for high frequencies, and a
delay in peak I latency that spreads
along the auditory pathway. These fea-
tures are similar to those observed in
the Igf1–/– mice (19,20) and also in pa-
tients carrying homozygous IGF1 muta-
tions (15,16). Therefore, understanding
Figure 2. General cochlear morphology. (A–F) Hematoxylin-eosin staining of midmodiolar
paraffin sections of the cochlea at postnatal wk 5 (A, B) and 11 (D-F) in Irs2+/+Ptpn1+/+,
Irs2–/–Ptpn1+/+ and Irs2–/–Ptpn1–/– mice. The general cochlear histology of both Irs2–/–Ptpn1+/+
and Irs2–/–Ptpn1–/– mutants (B, E, F) was similar to that in the wild-type mice (A, D), with no
obvious alterations, at either age studied. (C) Drawing scheme of the cochlear duct of the
basal turn (highlighted in B) and detail of the stria vascularis (StV, small rectangle), which is
formed by the basal (B), the intermediate (I) and the marginal (M) cell layers and contains
a dense capillary network. (G–I) Hematoxylin-eosin staining of the cochlear duct of the
basal turn in Irs2+/+Ptpn1+/+ (G), Irs2–/–Ptpn1+/+ (H) and Irs2–/–Ptpn1–/– mice (I) at postnatal wk
11. Both mutants showed a developed organ of Corti (OC), cochlear ganglion (SG), stria
vascularis (StV) and spiral ligament (SpL). The bracket and double head arrow indicate the
thickness of the stria vascularis and the spiral ligament, respectively. (J, L, N) Higher magnifi-
cation of the organ of Corti in Irs2+/+Ptpn1+/+, Irs2–/–Ptpn1+/+ and Irs2–/–Ptpn1–/– mice at post-
natal wk 11 illustrating that the outer hair cells (OHC) and inner hair cells (IHC), as well as
the surrounding supporting cells, were normal in appearance in both mutants (L, N) com-
pared with the control wild-type mice (J). (K, M, O) Myosin VIIa expression in the inner hair
cells (IHC) and outer hair cells (OHC) was unaffected in both mutants (M, O). Scale bars:
A, B, D–F, 500 μm; G–I, 100 μm; J–O 25 μm.
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the role of IRS2 in hearing function is
crucial to identify new sites for therapeu-
tic intervention on hearing loss. Interest-
ingly, Irs2–/–Ptpn1+/+ mice with obvious
hearing impairment at young ages usu-
ally developed a diabetic phenotype with
fasting hyperglycemia (>300 mg/dL) at
8–16 wks of life, and ABR data were
used as a predictive tool for type 2 dia-
betes diagnosis in mice.
Many clinical and epidemiological
studies have shown a direct relationship
between type 2 diabetes and hearing
loss, especially in the elderly, with a pat-
tern similar to presbycusis (42).
Histopathological findings in patients
with type 2 diabetes include cochlear
microangiopathy, degeneration of the
stria vascularis and outer hair cells (43).
Diabetes might affect the vasculature
and neural system of the inner ear, lead-
ing to hearing impairment that was
manifested in around 50% of the dia-
betic patients studied (44,45). In addi-
tion, genetic, pharmacological and nu-
tritional animal models were used to
study the effects of type 2 diabetes on
hearing (46,47). Vasilyeva et al. (47) re-
ported elevation of ABR thresholds as
early as 2 months after induction of
type 2 diabetes in CBA/CaJ mice. Simi-
larly, ob/ob C57BL/6J mice showed sig-
nificant differences in ABR thresholds
during aging compared with control
mice and histological findings that in-
clude outer hair cell degeneration and
loss of cochlear ganglion cells in the
middle and basal cochlear turns (46). In
contrast to these models of type 2 dia-
betes, the Irs2-null mice studied herein
Figure 3. Morphology of the stria vascularis. Hematoxylin-eosin staining of the stria vas-
cularis at the cochlear basal turn in Irs2+/+Ptpn1+/+ (A–D), Irs2–/–Ptpn1+/+ (G–J) and
Irs2–/–Ptpn1–/–mice (M–P) at 5 wks (left column) and 11 wks (right column) of age is
shown. Wild-type mice showed normal morphology, vasculature pattern and thickness
(bracket) of the stria vascularis (A–D). (B, D) Amplified detail of the stria vascularis illus-
trating the three epithelial layers, the basal, the intermediate and the marginal cell lay-
ers and the normal capillary network. Irs2–/–Ptpn1+/+ mice present numerous intercellular
spaces, probably because of degeneration of the marginal cells (arrows) and the
merging of the capillaries (dashed arrows) (G–J). At postnatal wk 5, Irs2–/–Ptpn1–/– mice
show a slight atrophy of the stria vascularis with few intercellular spaces (dashed arrows)
(M and N). The degeneration process worsens with age and 11-wk-old double-null mice
show severe atrophy and a number of merged capillaries (dashed arrows) (O, P). (E, F, K,
L, Q, R) Laser confocal microscopic examination showing Kir4.1 immunoreactivity (red).
In control mice, immunostaining appeared as a fold-like structure at the basolateral
side of marginal cells, designating the normal invaginations of these cells (dotted white
line in E and F). Both mutant mice show a significant reduction in Kir4.1 expression and
an irregular shape of the invaginations of the marginal cells (dotted white line in K, L, Q
and R). B, basal cells; C, capillary network; I, intermediate cells; M, marginal cell; StV, stria
vascularis. Scale bars: A, C, G, I, M, O: 50 μm; B, D, H, J, N, P: 25 μm; E, F, K, L, Q, R: 25 μm.
Figure 4. Cochlear volumes. Volume (mean
± SEM, mm3) of the tympanic (ST), media
(SM) and vestibular (SV) scalas and the spi-
ral ligament (SpL), stria vascularis (StV) and
cochlear ganglion (SG) in wild-type (n =
3), Irs2–/–Ptpn1+/+ (n = 4), and Irs2–/–Ptpn1–/–
(n = 4) mice at 11 wks of age is shown. The
smaller size of ST, SM and SpL in IRS2-
 deficient and double-null mice compared
with wild-type mice did not reach signifi-
cance. However, SG was significantly re-
duced in size in both IRS2-deficient (*P <
0.05) and double-null mice (##P < 0.01)
compared with wild-type mice; StV also
showed a decrease in volume, but only in
IRS2-deficient mice (*P < 0.05; **P < 0.01). 
, Irs2+/+Ptpn1+/+ mice; , Irs2–/–Ptpn1+/+
mice; , Irs2–/–Ptpn1–/– mice.
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showed hearing impairment at one
month of age before developing hyper-
glycemia, indicating that hearing loss is
not only a direct consequence of chroni-
cally raised glucose levels. These data
suggest that hearing evaluation may
have a prognostic value for the clinical
follow-up of diabetic patients.
In addition to the hearing impairment,
we have found that IRS2 deficit is associ-
ated with a reduced myelin P0 and neu-
rofilament staining in the cochlear gan-
glia. This hypoinnervation could be due
to a reduction in the number of nerve
fibers and/or in the myelin content.
IGF-1 is required for the late differentia-
tion of the cochlear ganglion neurons
and thus for the correct innervation of
the cochlea (24). Accordingly, the
cochlear ganglion of Igf1-null mice pre-
sents a significant decrease in the num-
ber and size of neurons and hypomyeli-
nation (20,22). These data suggest that
IGF-1 actions on the innervation of the
cochlear ganglia could be mediated by
signaling through IRS2.
IRS2-deficient mice also showed a de-
generation of the stria vascularis, simi-
lar but earlier than that observed in
aged 12-month-old Igf1–/– mice (20). De-
generation of the stria vascularis is a
common feature in presbycusis and in
other pathologies that deal with sen-
sorineural hearing loss such as systemic
hypertension, certain autoimmune dis-
eases and diabetes mellitus (43,48).
Histopathological findings in diabetic
Figure 5. Cochlear ganglion and nerve fibers. (A–C) Cresyl violet staining of midmodiolar
methacrylate sections of the cochlear ganglion at the cochlear basal turn in
Irs2+/+Ptpn1+/+ (A), Irs2–/–Ptpn1+/+ (B) and Irs2–/–Ptpn1–/–mice (C) at postnatal wk 11. A slight
reduction in the cellular density was more evident in both mutants (B, C) compared with
wild-type (A). (D–F) Myelin P0 immunostaining of the cochlear ganglion shows less intense
labeling in Irs2–/–Ptpn1+/+ (E) and Irs2–/–Ptpn1–/– (F) mice than in control mice (D). (G–I) Ac-
cordingly, myelin P0 immunostaining of nerve fibers projecting from the cochlear ganglion
to the sensory cells is less intense in Irs2–/–Ptpn1+/+ and Irs2–/–Ptpn1–/– (arrows in H and I)
than in wild-type mice (G). (J–L) Similarly, a weaker neurofilament 200-kDa immunostaining
is observed in Irs2+/+Ptpn1–/– (K, white arrow) and Irs2–/–Ptpn1–/– (L, white arrow) mice com-
pared with wild-type mice (J). Scale bars: A–I, 50 μm; J–L, 75 μm.
Figure 6. Cochlear morphology of the
Irs2+/+Ptpn1–/– mice. (A–D) Hematoxylin-
eosin staining of midmodiolar paraffin sec-
tions of the cochlea (A, B) and cochlear
ganglion (C, D) in wild-type and
Irs2+/+Ptpn1–/– mice at postnatal wk 11. No
gross differences were found. (E–H) Hema-
toxylin-eosin staining of the stria vascularis
at the cochlear basal turn in wild-type (E,
F) and Irs2+/+Ptpn1–/– (G, H) mice showed
normal morphology, vasculature pattern
and thickness in both genotypes. Details
of the stria vascularis (F, H) illustrating the
basal, intermediate and marginal cell lay-
ers and the normal capillary network are
shown. (I, J) Kir4.1 immunoreactivity (red)
revealed no evident differences between
genotypes. Scale bars: A, B: 500 μm; C, D,
E, G: 50 μm; F, H, I, J: 25 μm. B, basal cells;
C, capillary network; I, intermediate cells;
M, marginal cell.
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patients and animal models of diabetes
include alterations in the structure of
the marginal cells, widening of the strial
intercellular spaces and microvascular
disease (43,48) and are usually attrib-
uted to sustained raised glucose levels.
These changes are similar to that ob-
served in IRS2-deficient mice, even
without hyperglycemia. Delayed strial
degeneration in Irs2–/–Ptpn1–/– com-
pared with Irs2–/–Ptpn1+/+ mice might
be due to better metabolic control in the
double mutant, as it happens in the
liver (28).
In addition, Irs2–/–Ptpn1+/+ and
Irs2–/–Ptpn1–/– mice presented an al-
tered pattern of Kir4.1 immunoreactiv-
ity in the marginal cells when com-
pared with wild-type mice. Deletion or
changes in the expression of this chan-
nel, even without extensive degenera-
tion of the stria vascularis, compromise
the maintenance of the endocochlear
potential that allows sensory transduc-
tion (49,50).
PTP1B deficiency did not show any
obvious hearing phenotype at the ages
studied, but partially compensated the
prediabetic sensorineural hearing loss
caused by the lack of IRS2. Indeed,
young Irs2–/–Ptpn1–/– mice showed nor-
mal hearing function, but developed
neurosensorial deafness with increased
ABR thresholds at 8–16 wks of life. The
expression levels of PTP1B and its associ-
ation with the IR are increased in the
liver of hyperglycemic Irs2–/–/Ptpn1+/+
mice, resulting in a blockade of compen-
satory IR/IRS1-mediated insulin signal-
ing (28). Therefore, PTP1B deficiency
normalizes fasting blood glucose, fed
blood glucose, peripheral insulin sensi-
tivity and glucose tolerance in
Irs2–/–Ptpn1–/– mice at 12–16 wks of age,
compared with highly insulin-resistant
and glucose-intolerant Irs2–/–Ptpn1+/+
mice of the same age (28,34). In contrast,
the deaf phenotype observed in
Irs2–/–Ptpn1+/+ mice cannot be completely
reverted by deletion of the Ptpn1 gene,
which only delays the onset of hearing
loss in double-null mutant mice. These
results suggest that there are additional
players downstream of IRS2 signaling in-
volved in the development of hearing,
with this key issue deserving further in-
vestigation.
Our results show for the first time
that PTP1B is expressed in the cochlea
and that its expression is upregulated
by an IRS2 deficit, as reported in the
liver (28). Increased PTP1B expression
and activity cause dephosphorylation
of target receptors and blockade of
downstream signaling. Thus, PTP1B
upregulation has been proposed as the
molecular mechanism underlying the
loss of sensitivity to insulin in the liver
of hyperglycemic Irs2–/– mice. Accord-
ingly, lack of PTP1B in the double mu-
tant favors enhanced compensatory in-
tracellular response to insulin that in
the liver is mediated by IRS1 (28). Here
we report that damage of cochlear func-
tion in the IRS2 mutant is delayed
when PTP1B is absent, suggesting that
a similar mechanism is operating in the
cochlea.
CONCLUSION
In summary, the results presented in
this study demonstrate for the first time
a unique tissue-specific role of IRS2 in
cochlear development and hearing func-
tion; therefore, the Irs2–/– mouse could be
a novel model for the in vivo study of
hearing loss associated with altered glu-
cose metabolism. Our data also suggest
that modulation of PTP1B activity could
be a pharmacological target of interest
for the sensory syndromes associated
with diabetes.
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Figure 7. PTP1B, p-p38, p-MAPK and p-Akt
protein levels. PTP1B, p-p38, p-MAPK and
p-Akt levels were measured by Western
blotting in 5-wk-old mice cochleae. P38α
was used as a loading control to calcu-
late the relative protein levels. Values are
presented as mean ± SEM of at least
three mice per condition. Statistical signifi-
cance was estimated by t test; P values of
<0.05 were considered significant. PTP1B
expression levels were significantly in-
creased in Irs2–/–Ptpn1+/+ mice compared
with wild-type mice (*P < 0.05), and 
p-MAPK levels decreased when compar-
ing the double mutant with the wild-type
mice (*P < 0.05).
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